Market Intelligence, Clinical Progress, and High-Purity Reagents for Mucinous Adenocarcinoma Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MUC4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MUC4 ECD-Fc / EGF-like Domain Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View MUC4 Products |
| Gene Delivery | MUC4 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View MUC4 Products |
| Benchmark Ab | Anti-MUC4 Recombinant Antibody Recombinant positive control matching clinical-stage sequence clones. |
View MUC4 Products |
| Validator | MUC4 siRNA Set For target knockdown verification in pancreatic and breast cancer cell lines. |
View MUC4 Products |
| Related Target A | HER2 MUC4 physically interacts with HER2 via its EGF-like domain, masking HER2 epitopes and driving trastuzumab resistance. |
View HER2 Products |
| Related Target B | MUC1 Synergistic mucin family target overexpressed in epithelial cancers, sharing signaling pathways. |
View MUC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heavy O-glycosylation masking peptide epitopes | HEK293 expression host ensures native human-like glycosylation patterns for physiological epitope presentation. |
| MUC4-mediated HER2 masking in resistance assays | Lentivirus-mediated co-expression of MUC4 and HER2 in stable cell lines to model therapeutic resistance. |
| Lack of validated screening controls | Sequence-verified clinical benchmark antibodies and target-specific siRNA sets included for assay validation. |
| High background noise in ELISA/SPR | High purity (>95% by SDS-PAGE) and controlled endotoxin levels (<1.0 EU/µg) minimize non-specific binding. |
Live MUC4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MUC4 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and bispecific constructs. As first-generation therapies reach the clinic, the next wave of R&D is targeting the MUC4-HER2 interaction axis to overcome therapeutic resistance in solid tumors.
MUC4 is a massive transmembrane glycoprotein highly overexpressed in pancreatic, lung, breast, and ovarian cancers. Due to its bulky extracellular domain, MUC4 physically shields cell-surface receptors (like HER2), preventing therapeutic antibodies from binding. Developing targeted therapeutics requires highly specific reagents that can bind to accessible non-glycosylated loops or the EGF-like domains responsible for oncogenic signaling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Preclinical Programs / Biotech | Pancreatic Ductal Adenocarcinoma (PDAC), NSCLC | Internalization assays requiring high-purity, natively folded ECD-Fc proteins. |
| Bispecific Antibody (MUC4 x CD3) | Academic & Biotech Consortia | Refractory Ovarian Cancer, Breast Cancer | Dual-targeting validation using recombinant HER2/MUC4 protein panels. |
| Monoclonal Antibody (Blocking) | Translational Oncology Groups | Trastuzumab-resistant HER2+ Breast Cancer | In vitro blocking assays utilizing lentivirus-generated MUC4+ stable cell lines. |